Table 4.
One-step prediction accuracy of treatment simulation (with 95% CIs) based on out-of-bag evaluation of 1000 stratified bootstrapped samples.
| Predicted outcome | Accuracy without radiomics (%; 95% CI) | Accuracy with radiomics (%; 95% CI) |
| Overall survival (4 years) | 78.23 (73.20-82.92) | 78.95 (74.29-83.09) a |
| Feeding tube (6 months) | 74.37 (68.81-79.40) | 74.74 (68.53-80) |
| Aspiration rate after therapy | 75 (69.38-80) | 73.96 (68.04-78.76) |
| Prescribed chemotherapy (single, doublet, triplet, quadruplet, none, or not otherwise specified) | 83 (77.32-87.57) | 82.77 (78.06-87.13) |
| Chemotherapy modification (yes or no) | 82.09 (76.96-86.34) | 80.22 (75.98- 84.82) |
| Dose modified | 92.39 (89.23-94.95) | 94.50 (92.31-96.39) |
| Dose delayed | 92.39 (89.12-95.17) | 92.35 (88.56-95.52) |
| Dose cancelled | 91.58 (87.68-94.77) | 93.37 (90.05-96.15) |
| Regimen modification | 93.54 (84.36-95.88) | 91.79 (54.7-95.05) |
| DLTb (yes or no) | 81.51 (77.25-85.42) | 81.77 (77.34-85.79) |
| DLT: dermatological | 92.77 (23.95-95.29) | 90.58 (87.05-93.3) |
| DLT: neurological | 92.17 (88.66-95.1) | 92.27 (88.83-95.26) |
| DLT: gastrointestinal | 89.60 (85.86-92.96) | 90.36 (86.8-93.36) |
| DLT: hematological | 90.10 (86.17-93.23) | 91.84 (88.02-94.47) |
| DLT: nephrological | 99.03 (98-100) | 98.50 (96.55-99.52) |
| DLT: vascular | 98.45 (96.45-100) | 98.50 (96.86-100) |
| DLT: infection (pneumonia) | 98.98 (94.42-100) | 98.44 (96.37-99.50) |
| DLT: other | 95.08 (90.82-97.57) | 92.35 (83.17-96.98) |
| DLT: grade | 73.85 (53.84-79.9) | 77.02 (72.55-81.48) |
| No imaging (0=no and 1=yes) | 100 (100-100) | 100 (100-100) |
| Complete response, primary | 83.51 (78.82-87.56) | 84.02 (79.58-88.05) |
| Complete response, nodal | 94.79 (90.5-97.03) | 94.82 (89.64-97.4) |
| Parietal response, primary | 81.47 (76.84-86.27) | 80.32 (75.89-84.85) |
| Parietal response, nodal | 92.93 (90-95.65) | 92.93 (90.05-95.52) |
| Stable disease, primary | 95.10 (91.96-97.84) | 96.35 (92.96-98.03) |
| Stable disease, nodal | 96.58 (94.47-98.05) | 97.50 (96.08-98.55) |
| Concurrent chemotherapy regimen | 70 (64.68-75.27) | 65.99 (59.91-71.8) |
| Concurrent chemotherapy modification (yes or no) | 70.53 (64.92-76.06) | 71.43 (65.68-76.68) |
| Complete response, primary 2 | 79.22 (23.03-85.22) | 77.35 (29.95-84.57) |
| Complete response, nodal 2 | 55.50 (49.01-61.54) | 56.25 (50-61.94) |
| Parietal response, primary 2 | 78.92 (74.26-83.25) | 83.66 (79.90-86.60) |
| Parietal response, nodal 2 | 52.50 (46.19-58.03) | 52.85 (46.46-58.62) |
| Stable disease, primary 2 | 99.48 (98.46-100) | 99.48 (98.41-100) |
| Stable disease, nodal 2 | 96.50 (94.12-98.04) | 96.92 (94.36-98.45) |
| DLT: dermatological 2 | 91.99 (87.63-95.17) | 94.95 (91.53-97.07) |
| DLT: neurological 2 | 95.79 (5.96-97.46) | 91.97 (88.29-94.69) |
| DLT: gastrointestinal 2 | 89.74 (85.22-93.65) | 91.13 (87.50-94.06) |
| DLT: hematological 2 | 92.71 (89.42-95.16) | 93.23 (90.10-95.57) |
| DLT: nephrological 2 | 92.25 (88.17-97.94) | 96.53 (93.62-98.48) |
| DLT: vascular 2 | 100 (99.45-100) | 100 (99.02-100) |
| DLT: other 2 | 93.97 (89.73-96.86) | 93.24 (89.23-96.14) |
aValues in italics indicate whether higher accuracy is achieved by including or excluding radiomics.
bDLT: dose-limiting toxicity.